Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNA2 | P20248 | 1/20 | 0.49 |
| ▸ | CDK2 | P24941 | 1/20 | 0.49 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.49 |
| ▸ | F10 | P00742 | 18/20 | 0.49 |
| ▸ | F2 | P00734 | 3/20 | 0.49 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3885017 | 0.90 | F10 (0.56) | F10F2SLC29A1 | |
| SCHEMBL3879293 | 0.90 | CCNA2 (0.56) | CCNA2CDK2CCNA1F10F2 | |
| SCHEMBL15628280 | 0.87 | CCNA2 (0.47) | CCNA2CDK2CCNA1F10F2 | |
| SCHEMBL3872417 | 0.86 | CCNA2 (0.52) | CCNA2CDK2CCNA1F10F2 | |
| SCHEMBL1997488 | 0.86 | ALDH1A1 (0.51) | F10F2 | |
| SCHEMBL14350836 | 0.85 | PDE4A (0.49) | F10F2 | |
| SCHEMBL3873568 | 0.84 | F10 (0.69) | F10F2SLC29A1 | |
| SCHEMBL1996263 | 0.84 | F10 (0.69) | CCNA2CDK2CCNA1F10F2 | |
| SCHEMBL16179033 | 0.84 | F10 (0.47) | F10F2SLC29A1 | |
| SCHEMBL2003465 | 0.83 | F10 (0.45) | F10F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110894196-A | Lactam-containing compounds and derivatives thereof as factor Xa inhibitors | 百时美-施贵宝控股爱尔兰无限公司 | 2020-03-20 | — | — | CN | claimed |
| US-20170291896-A1 | PYRAZOLO[3,4-C]PYRIDINE DERIVATIVES | CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD. (CN) | 2017-10-12 | — | — | US | claimed |
| EP-3190111-A1 | PYRAZOLO[3,4-C]PYRIDINE DERIVATIVES | CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. (CN) | 2017-07-12 | — | — | EP | claimed |
| EP-2105436-A1 | Lactam-containing compounds and derivatives thereof as factor XA inhibitors | Bristol-Myers Squibb Company (US) | 2009-09-30 | — | — | EP | claimed |
| US-7388096-B2 | Crystalline forms of a factor Xa inhibitor | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-06-17 | — | — | US | claimed |
| US-7371761-B2 | Lactam-containing compounds and derivatives thereof as factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-05-13 | — | — | US | claimed |
| EP-1819703-A1 | CRYTALLINE FORMS OF A PYRAZOLO `3, 4-C Ü PYRIDINE FACTOR XA INHIBITOR | Brystol-Myers Squibb Company (US) | 2007-08-22 | — | — | EP | claimed |
| US-20070135426-A1 | LACTAM-CONTAINING COMPOUNDS AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-14 | — | — | US | claimed |
| WO-2006036927-A1 | CRYTALLINE FORMS OF A PYRAZOLO `3, 4-C ! PYRIDINE FACTOR XA INHIBITOR | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-04-06 | — | — | WO | claimed |
| US-20060069118-A1 | Crystalline forms of a factor Xa inhibitor | BRISTOL-MYERS SQUIBB COMPANY | 2006-03-30 | — | — | US | claimed |
| US-7005435-B2 | Lactam-containing compounds and derivatives thereof as factor Xa inhibitors | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2006-02-28 | — | — | US | claimed |
| US-20050267097-A1 | blood coagulation factor (trypsin-like serine protease enzymes) inhibitor; 3-(4-methoxy-phenyl)-5-[4-(2-oxo-2H-pyridin-1-yl)-phenyl]-3,5,6,7-tetrahydro-[1,2,3]triazolo4,5-c]pyridin-4-one; anticoagulant; cardiovascular thromboembolic disorder transient ischemic attack, stroke, atherosclerosis | BRISTOL-MYERS SQUIBB COMPANY | 2005-12-01 | — | — | US | claimed |
| US-20050261287-A1 | Lactam-containing compounds and derivatives thereof as factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2005-11-24 | — | — | US | claimed |
| US-6967208-B2 | Lactam-containing compounds and derivatives thereof as factor Xa inhibitors | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2005-11-22 | — | — | US | claimed |
| US-20050124602-A1 | Lactam-containing compounds and derivatives thereof as factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2005-06-09 | — | — | US | claimed |
| US-20040220174-A1 | Lactam-containing compounds and derivatives thereof as factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-11-04 | — | — | US | claimed |
| US-20030191115-A1 | Lactam-containing compounds and derivatives thereof as factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2003-10-09 | — | — | US | claimed |
| US-20200140436-A1 | LACTAM-CONTAINING COMPOUNDS AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2020-05-07 | — | — | US | disclosed |
| US-20040220174-A1 | Lactam-containing compounds and derivatives thereof as factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-11-04 | — | — | US | disclosed |
| US-20030191115-A1 | Lactam-containing compounds and derivatives thereof as factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2003-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170291896-A1 | PYRAZOLO[3,4-C]PYRIDINE DERIVATIVES | F11, TFPI, F2 | CCNA2 4397/4885CDK2 1139/4885CCNA1 3280/4885 |
| US-20060069118-A1 | Crystalline forms of a factor Xa inhibitor | F12, SERPINC1, F2 | CCNA2 2391/4885CDK2 533/4885CCNA1 1790/4885 |
| US-20050261287-A1 | Lactam-containing compounds and derivatives thereof as factor Xa inhibitors | F12, F2, CPB1 | CCNA2 1316/4885CDK2 857/4885CCNA1 946/4885 |
| US-20040220174-A1 | Lactam-containing compounds and derivatives thereof as factor Xa inhibitors | PEPD, PRSS1, CPB1 | CCNA2 2811/4885CDK2 1542/4885CCNA1 2471/4885 |
| US-20050124602-A1 | Lactam-containing compounds and derivatives thereof as factor Xa inhibitors | F12, F2, CPB1 | CCNA2 1313/4885CDK2 801/4885CCNA1 997/4885 |
| US-20050267097-A1 | blood coagulation factor (trypsin-like serine protease enzymes) inhibitor; 3-(4-methoxy-phenyl)-5-[4-(2-oxo-2H-pyridin-1-yl)-phenyl]-3,5,6,7-tetrahydro-[1,2,3]triazolo4,5-c]pyridin-4-one; anticoagulant; cardiovascular thromboembolic disorder transient ischemic attack, stroke, atherosclerosis | PLAT, F2, TFPI | CCNA2 1067/4885CDK2 261/4885CCNA1 476/4885 |
| US-20200140436-A1 | LACTAM-CONTAINING COMPOUNDS AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS | F12, F2, CPB1 | CCNA2 1313/4885CDK2 801/4885CCNA1 997/4885 |
| US-20030191115-A1 | Lactam-containing compounds and derivatives thereof as factor Xa inhibitors | PEPD, HABP2, CPB1 | CCNA2 3625/4885CDK2 2359/4885CCNA1 2128/4885 |
| US-20070135426-A1 | LACTAM-CONTAINING COMPOUNDS AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS | F12, F2, CPB1 | CCNA2 1313/4885CDK2 801/4885CCNA1 997/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.